 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| botulinum toxin type A (ATGC-110) / ATGC Co
Enrollment closed: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin (clinicaltrials.gov) - Feb 3, 2023
P3, N=300, Active, not recruiting, Sponsor: ATGC Co., Ltd.
Recruiting --> Active, not recruiting
- |||||||||| botulinum toxin type A (ATGC-110) / ATGC Co
New P3 trial: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin (clinicaltrials.gov) - Nov 21, 2022
P3, N=300, Recruiting, Sponsor: ATGC Co., Ltd.
- ||| botulinum toxin type A (ATGC-110) / ATGC Co
Trial completion: A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=60, Completed, Sponsor: ATGC Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | botulinum toxin type A (ATGC-110) / ATGC Co
New P1/2 trial: A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - Feb 24, 2020
P1/2, N=60, Active, not recruiting, Sponsor: ATGC Co., Ltd.